Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study
The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. We obtained random cross-sectional samples of adults from the National Health Service (...
Gespeichert in:
| Veröffentlicht in: | American journal of public health (1971) 2023-11, Vol.113 (11), p.1201-1209 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1209 |
|---|---|
| container_issue | 11 |
| container_start_page | 1201 |
| container_title | American journal of public health (1971) |
| container_volume | 113 |
| creator | Ward, Helen Atchison, Christina Whitaker, Matthew Davies, Bethan Ashby, Deborah Darzi, Ara Chadeau-Hyam, Marc Riley, Steven Donnelly, Christl A Barclay, Wendy Cooke, Graham S Elliott, Paul |
| description | The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.
We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020-May 2021).
We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.
REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance. (
2023;113(11):1201-1209. https://doi.org/10.2105/AJPH.2023.307381). |
| doi_str_mv | 10.2105/AJPH.2023.307381 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10568505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2886081228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-7717f2dae107f39af4348856bd4e955f37c96151eb1ba4b33d9881c1ad6774da3</originalsourceid><addsrcrecordid>eNpdkc1u1DAUhS0EokNhzwpZYsMmg3-S2GGDomFoBxWoOlO2lhM7qavEntpOpT5JX7cOUypg5Wv7u8c-9wDwFqMlwaj4WH87P10SROiSIkY5fgYWuMhxhlDOn4MFQhVKNS2PwKsQrhHCuCrwS3BEGaO0qugC3H_RwfQWSqvgZtwPetQ2ymicha6DEv74XcsBnnvXeznC6OB3Z010HsYrnY71rRy0bfXMb-uLbbZyvzICN_0JrG00jVNGB2gsXNt-mJ-5DMb2cKuHLtvpENPmE9wlqYt1vdqlzm2c1N1r8KKTQ9BvHtdjcPl1vVudZmc_Tzar-ixrKacxYwyzjiipMWIdrWSX05zzomxUrqui6ChrqxIXWDe4kXlDqao4xy2WqmQsV5Ieg88H3f3UjFq1yb2Xg9h7M0p_J5w04t8ba65E725FGn_JC1QkhQ-PCt7dTMmQGE1o9ZC8ajcFQXjJMckpIQl9_x967SafpjtTvESJIzxR6EC13oXgdff0G4zEHLuYYxdz7OIQe2p597eLp4Y_OdMHAxqncw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886081228</pqid></control><display><type>article</type><title>Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study</title><source>MEDLINE</source><source>PAIS Index</source><source>Business Source Complete</source><source>Education Source (EBSCOhost)</source><creator>Ward, Helen ; Atchison, Christina ; Whitaker, Matthew ; Davies, Bethan ; Ashby, Deborah ; Darzi, Ara ; Chadeau-Hyam, Marc ; Riley, Steven ; Donnelly, Christl A ; Barclay, Wendy ; Cooke, Graham S ; Elliott, Paul</creator><creatorcontrib>Ward, Helen ; Atchison, Christina ; Whitaker, Matthew ; Davies, Bethan ; Ashby, Deborah ; Darzi, Ara ; Chadeau-Hyam, Marc ; Riley, Steven ; Donnelly, Christl A ; Barclay, Wendy ; Cooke, Graham S ; Elliott, Paul</creatorcontrib><description>The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.
We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020-May 2021).
We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.
REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance. (
2023;113(11):1201-1209. https://doi.org/10.2105/AJPH.2023.307381).</description><identifier>ISSN: 0090-0036</identifier><identifier>ISSN: 1541-0048</identifier><identifier>EISSN: 1541-0048</identifier><identifier>DOI: 10.2105/AJPH.2023.307381</identifier><identifier>PMID: 37733993</identifier><language>eng</language><publisher>United States: American Public Health Association</publisher><subject>Adult ; Adults ; Age ; Antibodies ; Antibodies, Viral ; Antigens ; Community ; Community Health ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - epidemiology ; COVID-19 vaccines ; Cross-Sectional Studies ; Data analysis ; Data collection ; Data processing ; Data systems ; Deprivation ; Design ; Disease transmission ; England - epidemiology ; Epidemiology ; Estimates ; Ethnic factors ; Ethnic groups ; Fieldwork ; Health services ; Humans ; IgG antibody ; Immunization ; Immunoassay ; Immunoglobulin G ; Immunoglobulins ; Infections ; Minority & ethnic groups ; Pandemics ; Pilot projects ; Policy making ; Prevalence ; Proteins ; Public health ; Registration ; Research & Analysis ; Sample size ; SARS-CoV-2 ; Self testing ; Severe acute respiratory syndrome coronavirus 2 ; State Medicine ; Statistics/Evaluation/Research ; Surveillance</subject><ispartof>American journal of public health (1971), 2023-11, Vol.113 (11), p.1201-1209</ispartof><rights>Copyright American Public Health Association Nov 2023</rights><rights>American Public Health Association 2023 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-7717f2dae107f39af4348856bd4e955f37c96151eb1ba4b33d9881c1ad6774da3</citedby><cites>FETCH-LOGICAL-c383t-7717f2dae107f39af4348856bd4e955f37c96151eb1ba4b33d9881c1ad6774da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27866,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37733993$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ward, Helen</creatorcontrib><creatorcontrib>Atchison, Christina</creatorcontrib><creatorcontrib>Whitaker, Matthew</creatorcontrib><creatorcontrib>Davies, Bethan</creatorcontrib><creatorcontrib>Ashby, Deborah</creatorcontrib><creatorcontrib>Darzi, Ara</creatorcontrib><creatorcontrib>Chadeau-Hyam, Marc</creatorcontrib><creatorcontrib>Riley, Steven</creatorcontrib><creatorcontrib>Donnelly, Christl A</creatorcontrib><creatorcontrib>Barclay, Wendy</creatorcontrib><creatorcontrib>Cooke, Graham S</creatorcontrib><creatorcontrib>Elliott, Paul</creatorcontrib><title>Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study</title><title>American journal of public health (1971)</title><addtitle>Am J Public Health</addtitle><description>The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.
We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020-May 2021).
We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.
REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance. (
2023;113(11):1201-1209. https://doi.org/10.2105/AJPH.2023.307381).</description><subject>Adult</subject><subject>Adults</subject><subject>Age</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>Community</subject><subject>Community Health</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 vaccines</subject><subject>Cross-Sectional Studies</subject><subject>Data analysis</subject><subject>Data collection</subject><subject>Data processing</subject><subject>Data systems</subject><subject>Deprivation</subject><subject>Design</subject><subject>Disease transmission</subject><subject>England - epidemiology</subject><subject>Epidemiology</subject><subject>Estimates</subject><subject>Ethnic factors</subject><subject>Ethnic groups</subject><subject>Fieldwork</subject><subject>Health services</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunization</subject><subject>Immunoassay</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Infections</subject><subject>Minority & ethnic groups</subject><subject>Pandemics</subject><subject>Pilot projects</subject><subject>Policy making</subject><subject>Prevalence</subject><subject>Proteins</subject><subject>Public health</subject><subject>Registration</subject><subject>Research & Analysis</subject><subject>Sample size</subject><subject>SARS-CoV-2</subject><subject>Self testing</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>State Medicine</subject><subject>Statistics/Evaluation/Research</subject><subject>Surveillance</subject><issn>0090-0036</issn><issn>1541-0048</issn><issn>1541-0048</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7TQ</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1u1DAUhS0EokNhzwpZYsMmg3-S2GGDomFoBxWoOlO2lhM7qavEntpOpT5JX7cOUypg5Wv7u8c-9wDwFqMlwaj4WH87P10SROiSIkY5fgYWuMhxhlDOn4MFQhVKNS2PwKsQrhHCuCrwS3BEGaO0qugC3H_RwfQWSqvgZtwPetQ2ymicha6DEv74XcsBnnvXeznC6OB3Z010HsYrnY71rRy0bfXMb-uLbbZyvzICN_0JrG00jVNGB2gsXNt-mJ-5DMb2cKuHLtvpENPmE9wlqYt1vdqlzm2c1N1r8KKTQ9BvHtdjcPl1vVudZmc_Tzar-ixrKacxYwyzjiipMWIdrWSX05zzomxUrqui6ChrqxIXWDe4kXlDqao4xy2WqmQsV5Ieg88H3f3UjFq1yb2Xg9h7M0p_J5w04t8ba65E725FGn_JC1QkhQ-PCt7dTMmQGE1o9ZC8ajcFQXjJMckpIQl9_x967SafpjtTvESJIzxR6EC13oXgdff0G4zEHLuYYxdz7OIQe2p597eLp4Y_OdMHAxqncw</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Ward, Helen</creator><creator>Atchison, Christina</creator><creator>Whitaker, Matthew</creator><creator>Davies, Bethan</creator><creator>Ashby, Deborah</creator><creator>Darzi, Ara</creator><creator>Chadeau-Hyam, Marc</creator><creator>Riley, Steven</creator><creator>Donnelly, Christl A</creator><creator>Barclay, Wendy</creator><creator>Cooke, Graham S</creator><creator>Elliott, Paul</creator><general>American Public Health Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7TQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>88J</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DPSOV</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KC-</scope><scope>L.-</scope><scope>L.0</scope><scope>LK8</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2L</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M2R</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202311</creationdate><title>Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study</title><author>Ward, Helen ; Atchison, Christina ; Whitaker, Matthew ; Davies, Bethan ; Ashby, Deborah ; Darzi, Ara ; Chadeau-Hyam, Marc ; Riley, Steven ; Donnelly, Christl A ; Barclay, Wendy ; Cooke, Graham S ; Elliott, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-7717f2dae107f39af4348856bd4e955f37c96151eb1ba4b33d9881c1ad6774da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Age</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>Community</topic><topic>Community Health</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 vaccines</topic><topic>Cross-Sectional Studies</topic><topic>Data analysis</topic><topic>Data collection</topic><topic>Data processing</topic><topic>Data systems</topic><topic>Deprivation</topic><topic>Design</topic><topic>Disease transmission</topic><topic>England - epidemiology</topic><topic>Epidemiology</topic><topic>Estimates</topic><topic>Ethnic factors</topic><topic>Ethnic groups</topic><topic>Fieldwork</topic><topic>Health services</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunization</topic><topic>Immunoassay</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Infections</topic><topic>Minority & ethnic groups</topic><topic>Pandemics</topic><topic>Pilot projects</topic><topic>Policy making</topic><topic>Prevalence</topic><topic>Proteins</topic><topic>Public health</topic><topic>Registration</topic><topic>Research & Analysis</topic><topic>Sample size</topic><topic>SARS-CoV-2</topic><topic>Self testing</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>State Medicine</topic><topic>Statistics/Evaluation/Research</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ward, Helen</creatorcontrib><creatorcontrib>Atchison, Christina</creatorcontrib><creatorcontrib>Whitaker, Matthew</creatorcontrib><creatorcontrib>Davies, Bethan</creatorcontrib><creatorcontrib>Ashby, Deborah</creatorcontrib><creatorcontrib>Darzi, Ara</creatorcontrib><creatorcontrib>Chadeau-Hyam, Marc</creatorcontrib><creatorcontrib>Riley, Steven</creatorcontrib><creatorcontrib>Donnelly, Christl A</creatorcontrib><creatorcontrib>Barclay, Wendy</creatorcontrib><creatorcontrib>Cooke, Graham S</creatorcontrib><creatorcontrib>Elliott, Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>Global News & ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>PAIS Index</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Business Premium Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>Politics Collection</collection><collection>ProQuest Central</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Politics Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ProQuest Biological Science Collection</collection><collection>ABI/INFORM global</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Political Science Database</collection><collection>Psychology Database</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>ProQuest Social Science Journals</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of public health (1971)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ward, Helen</au><au>Atchison, Christina</au><au>Whitaker, Matthew</au><au>Davies, Bethan</au><au>Ashby, Deborah</au><au>Darzi, Ara</au><au>Chadeau-Hyam, Marc</au><au>Riley, Steven</au><au>Donnelly, Christl A</au><au>Barclay, Wendy</au><au>Cooke, Graham S</au><au>Elliott, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study</atitle><jtitle>American journal of public health (1971)</jtitle><addtitle>Am J Public Health</addtitle><date>2023-11</date><risdate>2023</risdate><volume>113</volume><issue>11</issue><spage>1201</spage><epage>1209</epage><pages>1201-1209</pages><issn>0090-0036</issn><issn>1541-0048</issn><eissn>1541-0048</eissn><abstract>The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England.
We obtained random cross-sectional samples of adults from the National Health Service (NHS) patient list (near-universal coverage). We sent participants a lateral flow immunoassay (LFIA) self-test, and they reported the result online. Overall, 905 991 tests were performed (28.9% response) over 6 rounds of data collection (June 2020-May 2021).
We produced weighted estimates of LFIA test positivity (validated against neutralizing antibodies), adjusted for test performance, at local, regional, and national levels and by age, sex, and ethnic group and area-level deprivation score. In each round, fieldwork occurred over 2 weeks, with results reported to policymakers the following week. We disseminated results as preprints and peer-reviewed journal publications.
REACT-2 estimated the scale and variation in antibody prevalence over time. Community self-testing and -reporting produced rapid insights into the changing course of the pandemic and the impact of vaccine rollout, with implications for future surveillance. (
2023;113(11):1201-1209. https://doi.org/10.2105/AJPH.2023.307381).</abstract><cop>United States</cop><pub>American Public Health Association</pub><pmid>37733993</pmid><doi>10.2105/AJPH.2023.307381</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-0036 |
| ispartof | American journal of public health (1971), 2023-11, Vol.113 (11), p.1201-1209 |
| issn | 0090-0036 1541-0048 1541-0048 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10568505 |
| source | MEDLINE; PAIS Index; Business Source Complete; Education Source (EBSCOhost) |
| subjects | Adult Adults Age Antibodies Antibodies, Viral Antigens Community Community Health COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 vaccines Cross-Sectional Studies Data analysis Data collection Data processing Data systems Deprivation Design Disease transmission England - epidemiology Epidemiology Estimates Ethnic factors Ethnic groups Fieldwork Health services Humans IgG antibody Immunization Immunoassay Immunoglobulin G Immunoglobulins Infections Minority & ethnic groups Pandemics Pilot projects Policy making Prevalence Proteins Public health Registration Research & Analysis Sample size SARS-CoV-2 Self testing Severe acute respiratory syndrome coronavirus 2 State Medicine Statistics/Evaluation/Research Surveillance |
| title | Design and Implementation of a National Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-Testing: The REACT-2 Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A03%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20Implementation%20of%20a%20National%20Program%20to%20Monitor%20the%20Prevalence%20of%20SARS-CoV-2%20IgG%20Antibodies%20in%20England%20Using%20Self-Testing:%20The%20REACT-2%20Study&rft.jtitle=American%20journal%20of%20public%20health%20(1971)&rft.au=Ward,%20Helen&rft.date=2023-11&rft.volume=113&rft.issue=11&rft.spage=1201&rft.epage=1209&rft.pages=1201-1209&rft.issn=0090-0036&rft.eissn=1541-0048&rft_id=info:doi/10.2105/AJPH.2023.307381&rft_dat=%3Cproquest_pubme%3E2886081228%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2886081228&rft_id=info:pmid/37733993&rfr_iscdi=true |